E2F1 and metabolic dysfunction-associated steatotic liver disease: Compared with NAFLD mice injected with EVs-miR-223-3p inhibitor + LV-sh-NC, the expression of miR-223-3p showed no obvious change while E2F1 was notably reduced in response to EVs-miR-223-3p inhibitor + LV-sh-E2F1 (Figure 7a).